References
- 1. https://coronavirus.jhu.edu/map.html
- 2. Astuti I, Ysrafil. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. Diabetes Metab Syndr. 2020;14(4):407-412. doi:10.1016/j.dsx.2020.04.02010.1016/j.dsx.2020.04.020716510832335367
- 3. Criado PR, Abdalla BMZ, de Assis IC, van Blarcum de Graaff Mello C, Caputo GC, Vieira IC. Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res. 2020;69(8):745-756. doi:10.1007/s00011-020-01370-w10.1007/s00011-020-01370-w726638732488318
- 4. Gao Z, Xu Y, Sun C, et al. A Systematic Review of Asymptomatic Infections with COVID-19 [published online ahead of print, 2020 May 15]. J Microbiol Immunol Infect. 2020;10.1016/j.jmii.2020.05.001 doi. org/10.1016/j.jmii.2020.05.001
- 5. Chen Y, Wang AH, Yi B, Ding KQ, Wang HB, Wang JM, et al. The epidemiological characteristics of infection in close contacts of COVID-19 in Ningbo city[J/OL]. Chin J Epidemiol 2020:41. https://doi.org/10.3760/cma.j.cn112338-20200304-00251
- 6. Machhi J, Herskovitz J, Senan AM, et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections [published online ahead of print, 2020 Jul 21]. J Neuroimmune Pharmacol. 2020;1-28. doi:10.1007/s11481-020-09944-510.1007/s11481-020-09944-5737333932696264
- 7. Shurin MR, Morris A, Wells A, Wheeler SE. Assessing Immune Response to SARS-CoV-2 Infection. Immunotargets Ther. 2020;9:111-114. Published 2020 Jun 11. doi:10.2147/ITT.S26413810.2147/ITT.S264138729545532607314
- 8. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. doi:10.1002/JLB.3COVR0520-272R10.1002/JLB.3COVR0520-272R732325032534467
- 9. Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19(7):102567. doi:10.1016/j. autrev.2020.102567.
- 10. Carter-Timofte ME, Jørgensen SE, Freytag MR, et al. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol. 2020;11:1606. Published 2020 Jun 30. doi:10.3389/fimmu.2020.0160610.3389/fimmu.2020.01606733858832695122
- 11. Marietta, M., Coluccio, V. & Luppi, M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med (2020). https://doi.org/10.1007/s11739-020-02432-x10.1007/s11739-020-02432-x735208732653981
- 12. Ghazal, S., Litvinov, I. V., Aljahani, N., Jfri, A., & Netchiporouk, E. (2020). Cutaneous Manifestations of Coronavirus Disease 2019 (COVID-19) Infection—What Do We Know So Far? Journal of Cutaneous Medicine and Surgery, 24(4), 416–417. https://doi.org/10.1177/120347542092837510.1177/120347542092837532391713
- 13. Kaya, Gürkan & Kaya, Aysin & Saurat, Jean-Hilaire. (2020). Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature. Dermatopathology. 7. 3-16. 10.3390/dermatopathology7010002.10.3390/dermatopathology7010002758359332608380
- 14. Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77. doi:10.1111/bjd.1916310.1111/bjd.19163726723632348545
- 15. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. 2020.https://www.who.int/publications-etail/clinicalmanagement-of-severe-acute-respiratory-infection-whennovel-coronavirus-(ncov)-infection-is-suspected
- 16. Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: A systematic review [published online ahead of print, 2020 Jul 8]. Diabetes Metab Syndr. 2020;14(5):1133-1142. doi:10.1016/j.dsx.2020.07.00510.1016/j.dsx.2020.07.005
- 17. Tobaiqy M, Qashqary M, Al-Dahery S, et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020;2(3):100061. doi:10.1016/j.infpip.2020.10006110.1016/j.infpip.2020.100061
- 18. Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability [published online ahead of print, 2020 Aug 10]. Thromb Res. 2020;196:38-51. doi:10.1016/j.thromres.2020.08.01710.1016/j.thromres.2020.08.017
- 19. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi:10.1016/j.thromres.2020.04.02410.1016/j.thromres.2020.04.024
- 20. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13. doi:10.1016/j.trsl.2020.04.00710.1016/j.trsl.2020.04.007
- 21. Pons, Stéphanie & Fodil, Sofiane & Azoulay, Elie & Zafrani, Lara. (2020). The vascular endothelium: The cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Critical Care. 24. 10.1186/s13054-020-03062-7.10.1186/s13054-020-03062-7
- 22. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-510.1016/S0140-6736(20)30937-5
- 23. Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219-227. doi:10.1016/j.kint.2020.04.003.10.1016/j.kint.2020.04.003
- 24. Copin MC, Parmentier E, Duburcq T, Poissy J, Mathieu D; Lille COVID-19 ICU and Anatomopathology Group. Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 2020;46(6):1124-1126. doi:10.1007/s00134-020-06057-810.1007/s00134-020-06057-8
- 25. Bradley BT, Maioli H, Johnston R, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet (London, England). 2020 Aug;396(10247):320-332. DOI: 10.1016/s0140-6736(20)31305-2.10.1016/S0140-6736(20)31305-2
- 26. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. doi:10.1182/blood.202000600010.1182/blood.2020006000727382732339221
- 27. Marietta, M., Coluccio, V. & Luppi, M. COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Intern Emerg Med (2020). https://doi.org/10.1007/s11739-020-02432-x10.1007/s11739-020-02432-x735208732653981
- 28. Warkentin TE, Kaatz S. COVID-19 versus HIT hypercoagulability [published online ahead of print, 2020 Aug 10]. Thromb Res. 2020;196:38-51. doi:10.1016/j.thromres.2020.08.01710.1016/j.thromres.2020.08.017741671732841919
- 29. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020 Apr 6;:]. Intensive Care Med. 2020;46(5):846-848. doi:10.1007/s00134-020-05991-x10.1007/s00134-020-05991-x708011632125452
- 30. Fathi N, Rezaei N. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol Int. 2020;44(9):1792-1797. doi:10.1002/cbin.1140310.1002/cbin.11403728367232458561
- 31. Thevarajan I, Nguyen THO, Koutsakos M, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nature Medicine. 2020 Apr;26(4):453-455. DOI: 10.1038/s41591-020-0819-2.10.1038/s41591-020-0819-2709503632284614
- 32. Cecconi M, Piovani D, Brunetta E, et al. Early Predictors of Clinical Deterioration in a Cohort of 239 Patients Hospitalized for Covid-19 Infection in Lombardy, Italy. J Clin Med. 2020;9(5):1548. Published 2020 May 20. doi:10.3390/jcm905154810.3390/jcm9051548729083332443899
- 33. Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients [published online ahead of print, 2020 Jul 14]. Allergy. 2020;10.1111/all.14496. doi:10.1111/all.1449610.1111/all.14496740475232662525
- 34. Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128-136.e4. doi:10.1016/j.jaci.2020.05.00810.1016/j.jaci.2020.05.008723323932425269
- 35. Low SpO2: oxygen saturation below 95 %; Hb: haemoglobin; WBC: white blood cell count; CRP:c-reactive protein; PCT: procalcitonin; COPD: chronic obstructive pulmonary disease; CK-MB: creatine kinase isoensyme MB; # during evolution